You are here
Disease modifying therapies
Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trial
Samuel F. Hunter, Mark Agius, Deborah M. Miller, Gary Cutter, Luigi Barbato, Kevin McCague, Xiangyi Meng, Neetu Agashivala, Peter Chin, Eric Hollander
Journal of the Neurological Sciences, June 2016, Pages 190 - 198
Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life – A post hoc analysis of the TEMSO and TOWER studies
Mathias Mäurer, Giancarlo Comi, Mark S. Freedman, Ludwig Kappos, Tomas P. Olsson, Jerry S. Wolinsky, Aaron E. Miller, Catherine Dive-Pouletty, Sylvie Bozzi, Paul W. O’Connor
Multiple Sclerosis and Related Disorders, Volume 7, May 2016, Pages 33–40
Khaled Mohamed Mohamed Koriem
Asian Pacific Journal of Tropical Biomedicine, Volume 6, Issue 5, May 2016, Pages 429–440
Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trialThe Lancet Neurology, Volume 15, Issue 4, April 2016, Pages 373–381
A 12-month prospective, observational study evaluating the impact of disease-modifying treatment on emotional burden in recently-diagnosed multiple sclerosis patients: The POSIDONIA study
Enrico Montanari, Mariarosa Rottoli, Davide Maimone, Paolo Confalonieri, Katrin Plewnia, Maura Frigo, Ada Francia, Antonello Pala, Nunzia Alessandra Losignore, Paolo Ragonese, Antonella Veneziano, on behalf of the POSIDONIA study group.
Journal of the Neurological Sciences, May 2016, Pages 105 - 109
Autoimmunity Reviews, Volume 15, Issue 7, July 2016, Pages 714–718
Distribution-based estimates of minimum clinically important difference in cognition, arm function and lower body function after slow release-fampridine treatment of patients with multiple sclerosis
H.B. Jensen, Sepehr Mamoei, M. Ravnborg, U. Dalgas, E. Stenager
Multiple Sclerosis and Related Disorders, Volume 7, May 2016, Pages 58–60
- Data from recently completed clinical trials were presented at the 2016 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), held June 1-4 in National Harbor, MD. Patients of African-American descent typically experience a more-aggressive disease course of MS compared with Caucasians discussed Annette Okai...
- There is little information on the performance of disease-modifying drugs (DMDs) in the real world, according to Chris Kozma, an independent research consultant, Saint Helena Island, SC. Real world assessment of relapse rates of patients with MS comparing relapse rates between newer oral disease-modifying drugs (DMDs)...
Short-term suboptimal response criteria for predicting long-term non-response to first-line disease modifying therapies in multiple sclerosis: A systematic review and meta-analysis
Jordi Río, Juan Luís Ruiz-Peña
Journal of the Neurological Sciences, February 2016, Pages 158 - 167